|
|
||||||||
Department of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
| |
ABSTRACT |
|---|
|
|
|---|
The aim of this study was to elucidate the
role of thromboxane A2 (TxA2) on asthma-related
cough in guinea pigs. Animals were immunosensitized and repeatedly
challenged with ovalbumin as an antigen. Coughs were induced by the
inhalation of 10
5 M capsaicin solution for 10 min.
Thromboxane synthetase (TxS) inhibitor OKY-046 and thromboxane-receptor
antagonist AA-2414 significantly inhibited cough responses in
repeatedly challenged animals. Inhalation of TxA2 mimic
STA-2- potentiated cough responses in normal and immunosensitized
animals but not in repeatedly challenged ones. Moreover,
STA-2-potentiated coughs were inhibited by administration of
neurokinin-receptor antagonist FK-224. In repeatedly challenged animals, concentration of TxB2 in airway lavage fluid,
expression of TxS mRNA in tracheal epithelia, and the immunostaining
intensity against TxS in mucous cells of the epithelium significantly
increased compared with normal and sensitized animals. These results
suggest that TxA2 derived from mucous cells potentiated
cough responses to capsaicin in allergic airway inflammation.
allergic airway inflammation; capsaicin; guinea pigs; mRNA; airway lavage fluid
| |
INTRODUCTION |
|---|
|
|
|---|
COUGHING IS ONE OF THE major symptoms of bronchial asthma. The sole symptom of cough-variant asthma, a form of asthma, is chronic coughing (13, 20, 29). As a chronic inflammatory disorder of the airways, asthma is characterized by airflow limitation, which can include components of acute bronchoconstriction, airway edema, mucous plug formation, and airway wall remodeling (27). However, the precise mechanism by which airway inflammation in asthma causes coughing has not yet been elucidated.
Coughing is elicited by stimulation of sensory receptors in the respiratory tract that send impulses to the brain stem, which transmits signals to the larynx, intracostal muscles, diaphragm, and abdominals (41). We have previously reported the effect of airway inflammation on the cough response in guinea pigs (44), indicating that repeated immunochallenges induced the infiltration of inflammatory cells into the airways and increased cough sensitivity. Tachykinin-receptor antagonists inhibited the increased cough sensitivity. This finding demonstrates that the capsaicin-induced release of tachykinins plays an important role in the increased cough sensitivity of ovalbumin (OVA)-sensitized and repeatedly challenged guinea pigs.
The role of thromboxane A2 (TxA2) in the pathogenesis of asthma has been extensively studied (26, 35, 39). Thromboxane-receptor antagonist AA-2414 and selective thromboxane synthetase (TxS) inhibitor OKY-046 are commercially available as anti-asthma drugs in Japan. Moreover, it has been recently reported that a TxS inhibitor suppressed coughing induced by angiotensin-converting enzyme inhibitors and that cough threshold was increased by treatment of OKY-046 in asthmatics (38, 14). However, the precise production site and effective cells of TxA2 have not been fully determined.
TxA2 may play an important role in coughing that results from airway allergic inflammation. In the present study using a guinea pig cough model, we studied whether TxA2 was related to cough responses and investigated the relationships between TxA2 and tachykinins in cough responses. Furthermore, we elucidated the localization of TxS in guinea pig airways.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals. Experiments using animals were performed in accordance with the institutional guidelines set forth by the University of Tsukuba Committee on the Use and Care of Animals. Female Hartley guinea pigs (n = 153) weighing 250-300 g (SLC Farm, Shizuoka, Japan) were used for the following experiments. Animals were sensitized as described previously (2, 37). Briefly, guinea pigs were pretreated with an intraperitoneal injection of 30 mg/kg cyclophosphamide. Two days later, they were immunized with 1 mg OVA and 100 mg of aluminum hydroxide. Three weeks after primary immunization, a booster intraperitoneal injection 10 µg OVA together with 100 mg aluminum hydroxide was performed. Animals were used 6 wk after primary immunization.
To evaluate the effect of allergic inflammation on cough responses, we repeatedly exposed sensitized animals to aerosols of OVA (4 mg/ml saline) for 4 min daily for 7 days. Diphenhydramine (50 mg/kg) was injected intraperitoneally 30 min before each OVA challenge to protect animals from anaphylaxis.Measurement of cough responses.
The principle and detailed methods of measurement of cough responses
were described previously (44). Unanaesthetized guinea pigs were placed in an air-tight box and exposed to aerosol production of 10
5 M capsaicin solution for 10 min. An ultrasonic
nebulizer (NEU 03, Omron, Tokyo, Japan) produced aerosols containing
particles with an aerodynamic mass-median diameter of 5.0 µm
(manufacturer's specification) at 0.25 ml/min. Coughing was considered
to have occurred if a rapid violent movement of the chest was
distinguished by at least two observers. Pressure changes of the box
were recorded with a differential pressure transducer (model TP-602T,
Nihonkohden, Tokyo). Coughing sounds were recorded by a microphone
placed in front of a face mask, and cough waves were analyzed by a
computer connected with the microphone throughout the amplifier.
Coughing was detected and clearly distinguished from sneezing or other body movement with these methods. In all experiments, once a guinea pig
was exposed to capsaicin, it was never reused in subsequent experiments.
Pharmacological effect of TxA2 on cough responses.
To evaluate whether TxA2 is related to capsaicin-induced
coughing, TxA2-receptor agonist STA-2 was used instead of
unstable TxA.2. STA-2 was inhaled at concentrations of 3 × 10
7 M, 10
6 M, and 10
5 M for
10 min to induce a cough response, but it did not elicit coughing in
any group of guinea pigs. Next, we measured specific airway conductance
as an index of airflow limitation at the three doses listed above, as
described previously (19). Inhalation of STA-2 at doses of
10
6 and 10
5 M induced bronchoconstriction,
so we used a contractile subthreshold dose of 3 × 10
7 M for the experiment. Guinea pigs were pretreated
with inhalation of 3 × 10
7 M STA-2 for 5 min, and
30 min later they were challenged with an aerosol dose of
10
5 M capsaicin.
5 M, for 5 min) 30 min after pretreatment with
STA-2, and 30 min later they were exposed to capsaicin.
We also examined the effects of thromboxane inhibition. Sensitized and
repeatedly challenged guinea pigs were pretreated with OKY-046, a TxS
inhibitor, through a mini-osmotic pump (Alzet, Palo Alto, CA). The pump
flow moderator was implanted in the skin below the rib cage of the
animals. OKY-046 was at a dose of 50 µg · kg body
wt
1 · min
1 administered by
continuous infusion for 4 days from the implantation. This dosage has
been known pharmacologically to be effective enough to block TxS
(6). On day 5, the exposure of capsaicin was
performed. AA-2414, a TxA2-receptor antagonist, was
administered orally through a gastric tube at a dose of 10 mg/kg body
wt for 4 days in sensitized and repeatedly challenged animals. On
day 5, animals were exposed to capsaicin aerosols.
Enzyme immunoassay of TxB2 in airway lavage fluid.
To evaluate TxS in the airway, we measured the level of
TxB2 in the airway lavage fluid of three groups
(n = 5 in each group). Because TxA2
produced from alveolar macrophages is found in greater concentration in
bronchoalveolar lavage fluid (28), we used the
tracheobronchial lavage to lower this influence as much as possible.
For tracheobronchial lavage, the trachea was cannulated with a 16-gauge
tube under anesthesia with pentobarbital sodium (50 mg/kg ip). One
milliliter of ice-cold saline, including 10
5 M
indomethacin and 5 × 10
3 M EDTA, was slowly
injected into the trachea, and the recovered fluid was collected. These
procedures were repeated three times. The recovered fluid was
centrifuged at 150 g for 10 min at 4°C. Aliquots of the
supernatants were collected and stored at
20°C until the assay.
TxB2 was purified according to a manual protocol and was
assayed by using a TxB2 enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI). The sensitivity is 13.3 pg/ml and the specificity is 100% for TxB2.
Immunohistological analysis. Normal and repeatedly challenged guinea pigs (n = 4 in each group) were anesthetized as described above. Their tracheas were immediately removed and fixed with 4% paraformaldehyde in phosphate buffer (pH 7.2) for 2 h, washed with PBS (pH 7.4), and incubated in 5, 10, and 20% sucrose in PBS, respectively. Then the tracheas were embedded in optimum cutting temperature compound (Miles, Elkhart, IN) and frozen. Continuous cryosections (8 µm) were stained with immunohistochemical staining or periodic acid Schiff (PAS) to evaluate the immunohistochemical localization of TxS and the condition of mucous cells, respectively. For immunohistochemical staining, the sections were rehydrated with washing buffer (in M: 0.5 NaCl, 0.02 Tris, 0.01 CaCl2; pH = 7.4) for 10 min and then incubated with 2.3% periodic acid for 5 min, 0.02% potassium borohydride for 2 min, and 0.3% H2O2 in methanol for 30 min to block endogenous peroxidase activity. After immersion in 1% normal mouse serum in caseine for 30 min, the sections were incubated for 30 min at room temperature with a biotinylated mouse anti-human TxS monoclonal antibody (BMA Biomedicals, Augst, Switzerland) at a dilution of 1:20. Nonimmune mouse serum was used as a negative control. Sections were incubated with avidin-biotin-peroxidase complex (ABC kit, Vector Laboratories, Burlingame, CA). Reactions were visualized by 3,3'-diaminobenzidine tetrahydrochloride (DAB) (Dojindo, Kumamoto, Japan). Sections were used for light microscopic analysis after being counterstained with hematoxylin. For electron-microscopic analysis, sections were fixed with 2% glutaraldehyde in PBS (0.1 M, pH 7.4) after reaction with DAB and postfixed in 2% osmium tetroxide in PBS (0.1 M, pH 7.4) for 4 h. Sections were then dehydrated in a graded series of ethanol (50-100%) followed by propylene oxide, and embedded in Poly/Bed 812 resin (Polysciences, Warrington, PA) for transmission electron microscopy. Ultrathin sections of 100-150 nm were cut by using an Ultrotome Laboratoire Kastler Brossel 2088 (LKB-Producter, Bromma, Sweden) and observed with an electron microscope (H-7000, Hitachi, Tokyo). PAS staining was performed by oxidizing sections in 0.5% periodic acid for 5 min, staining with Schiff's reagent for 7 min and hematoxylin for 30 s, and then dedifferentiating with 1% HCl in 70% ethanol for 3 s.
Western blot analysis.
The specificity for the TxS antibody against guinea pigs was tested by
Western blot analysis with the protein of guinea pig platelets. The
blood of five guinea pigs was obtained with cardiac puncture under
anesthesia, as described above, and collected into 0.1 volume, 3.8%
(wt/vol) trisodium citrate. Platelet-rich plasma was prepared by
centrifugation for 20 min at 200 g at 20°C. Platelet-rich plasma was then centrifuged for 10 min at 800 g. The pellet
was mixed with an equal volume of loading buffer (125 mM
Tris · HCl, pH 6.8; 4% SDS, 20% glycerol, 0.05% bromophenol
blue, 5%
-mercaptoethanol) and boiled for 3 min. SDS-PAGE was
performed on equivalent protein samples with 10% acrylamide, and
protein was electrophoretically transferred to polyvinylidene
difluoride membrane (Bio-Rad Laboratories, Hercules, CA). Membranes
were blocked in buffer containing 5% dried milk and 1% normal mouse
serum for 60 min. They were incubated with 1:20 TxS antibody for 30 min
and then with the ABC kit and stained with an AP conjugate substrate
kit (Bio-Rad Laboratories).
Cloning of TxS complement DNA fragments from guinea pig lungs. To examine the expression of TxS mRNA, we cloned TxS cDNA fragments from the lungs of guinea pigs. Total RNA was extracted from lungs (n = 2) with an RNeasy total RNA kit (Qiagen, Hilden, Germany). A 514-bp DNA fragment was obtained by RT-PCR by using a GeneAmp RNA PCR kit (Perkin Elmer, Foster City, CA) with the gene-specific primers 5'-CAGACATGATCA AGCAGGTG-3' and 5'-GCAATCACATTCCTAATGAG-3'. PCR product was subcloned into a cloning vector with vector pGEM-T and pGEM-T Easy Vector Systems (Promega, Madison, WI) and sequenced by the dideoxynucleotide chain-termination method by using a dideoxyterminator kit (Perkin Elmer) and a DNA sequencer model 373S (Perkin Elmer Applied Biosystems Division, Foster City, CA).
Northern blot analysis. Levels of TxS mRNA in the airway epithelium were compared by Northern blot analysis among normal, sensitized, and multiply challenged groups (n = 5 in each group). Tracheas were carefully dissected free from surrounding connective tissue and incised along the ventral midline. The epithelial side of the trachea was gently scraped with a rubber scraper in the presence of PBS. Total RNA of the epithelial layer was extracted by using Tryzol Reagent (Life Technologies, Grand Island, NY). Ten micrograms of total RNA obtained from each animal were separated on 4% formaldehyde-1% agarose gel and transferred to Hybond N+ nylon membrane filter (Amersham). The 514-bp TxS cDNA fragment was labeled by 32P deoxycytidine triphosphate and further used as a probe. RNA was hybridized with the cDNA probe in ExpressHyb hybridization solution (Clontech, Palo Alto, CA) at 68°C and washed with 0.1× SSC-0.1% SDS (SSC is 0.15 M NaCl-0.015 M sodium citrate) at 50°C. The membrane was exposed to a BAS-SR imaging plate (Fuji Film, Tokyo) and analyzed with a BAS-5000 imaging analyzer (Fuji Film).
Preparation of drugs.
Capsaicin (Sigma Chemical, St. Louis, MO) was dissolved in saline
containing 10% ethanol and 10% Tween 80 to give stock solutions of
10
2 M, which were stored at 4°C. FK-224 (kind gift from
Fujisawa Pharmaceutical, Osaka, Japan) was dissolved in dimethyl
sulfoxide to give a 0.1 M stock solution, which was stored at 4°C.
These stock solutions were diluted in saline as necessary for each
experiment. STA-2 (kind gift from ONO Pharmaceutical, Osaka, Japan) was
dissolved in phosphate buffer (1/15 M, pH 7.2) to give a stock solution of 10
2 M, which was stored at 4°C and diluted in the
same buffer. OKY-046 (kind gift from ONO) was dissolved in ethanol to
320 mg/ml and diluted in saline to 128 mg/ml. AA-2414 (kind gift from
Takeda Pharmaceutical, Osaka, Japan) was dissolved in saline containing 10% ethanol. All other drugs were obtained from Wako Pure Chemicals (Osaka, Japan) and dissolved in saline. Drugs' doses were calculated as their free base.
Statistical analysis. Results are presented as means ± SE. Statistical analysis was performed among three groups or between two groups. Data for capsaicin-induced coughing under baseline conditions and TxB2 concentration in three groups were analyzed by one-way ANOVA and post hoc Fisher's paired least-significant difference test. Differences between vehicle and drug pretreatment groups were evaluated with an F test and then with a Student's t-test. Significant differences were accepted when P value was <0.05.
| |
RESULTS |
|---|
|
|
|---|
Facilitation of the effect of TxA2 on cough responses.
Effects of STA-2 on capsaicin-induced coughing are shown in Fig.
1. Values for cough under baseline
conditions were significantly different in normal vs. sensitized
animals (5.17 ± 1.01 vs. 10.0 ± 1.53, P < 0.05) and normal vs. repeatedly challenged ones (5.17 ± 1.01 vs.
22.5 ± 1.52, P < 0.01). Inhalation of STA-2
caused a significant increase in the number of coughs in normal and
sensitized animals compared with the vehicle (22.17 ± 5.05 vs.
5.17 ± 1.01, P < 0.01 and 31.0 ± 3.0 vs.
10.0 ± 1.53, P < 0.01, respectively). Repeatedly
immunochallenged guinea pigs, however, did not show a significant
increase (20.17 ± 1.79 vs. 22.5 ± 1.52).
|
|
|
Level of TxB2 in airway lavage fluid.
To examine whether production of TxA2 was augmented in
sensitized and repeatedly challenged animals, levels (pg/ml) of
TxB2 in airway lavage fluid were assayed. Immunoreactive
TxB2 in the fluid of the repeatedly challenged group was
significantly greater than that of the normal (874.40 ± 111.62 vs. 490.64 ± 88.90, P < 0.05) and sensitized
groups (874.40 ± 111.62 vs. 571.04 ± 88.78, P < 0.05) (Fig. 4).
|
Immunohistochemical localization of TxS in the airway.
The result of Western blot analysis demonstrated the specificity of
anti-human TxS antibody for guinea pigs. A single band of ~58 kDa was
observed (Fig. 5). PAS staining showed
that the subtracheal gland was stained darkly (Fig.
6a), and mucous cells markedly
increased in multiply challenged animals compared with normal animals
(data not shown). Immunohistochemical analysis of TxS showed that
subtracheal gland and epithelial cells of the trachea were partly
stained (Fig. 6, b-d). Only scattered staining was
observed in normal animals. In contrast, prominent staining was seen in
multiply challenged guinea pigs. No immunoreactivity was detected with
nonimmune mouse serum in any group. Immunoelectron microscopic analysis
revealed that immunoreactive TxS was present in the cytosol of
epithelial goblet cells, especially around secretion granules (Fig.
7).
|
|
|
Nucleotide sequence of a TxS cDNA fragment from guinea pig lung.
The nucleotide sequence of a 514-bp TxS cDNA fragment of guinea pig
lung was elucidated (Fig. 8). It is
highly homologous to human TxS (83.3% identity) (30),
mouse TxS (80.0% identity) (45), and rat TxS (80.5%
identity) (36). The obtained clone, therefore, was
considered to encode a part of the guinea pig TxS.
|
Expression of TxS mRNA.
TxS mRNA levels of tracheal epithelial layers in normal, sensitized,
and multiply challenged guinea pigs are shown in Fig. 9. Only one band with a size of ~2.1 kb
was observed. TxS mRNA expression in multiply challenged animals was
markedly greater than in normal and sensitized animals. In contrast,
TxS expressions of the lung parenchyma and the whole tracheal membrane
portion did not show any differences among the three groups (data not show). These data indicate that the main site of expression of TxS mRNA
is the epithelial layer in the airway.
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, treatment with TxS inhibitor OKY-046 and thromboxane-receptor antagonist AA-2414 prevented cough responses, which were shown to increase as a result of repeated immunochallenges. STA-2, a TxA2 mimic, potentiated cough responses in normal and immunosensitized animals but not in repeatedly challenged ones. These results indicate that TxA2 could facilitate coughing.
Coughing can be induced by the stimulation of sensory nerves in the airway (23). There are two types of cough receptors in the mucosa of the larynx and tracheobronchial tree: myelinated rapidly adapting receptors (RARs) and nonmyelinated C fiber receptors (3, 4, 5, 21, 42). Capsaicin, a powerful tussigenic agent in humans and other species, can act on those cough receptors with the release of tachykinins from the latter, further stimulating RARs and causing a cough response (41). We thought TxA2 might also induce cough responses because Karla et al. (22) reported that TxA2 could stimulate pulmonary C fiber endings predominantly and directly. However, our data show that inhalation of STA-2 enhanced capsaicin-induced cough (Fig. 1) but did not directly induce coughing. These data indicate that TxA2-facilitated cough responses are not associated with the direct stimulation of C fiber receptors.
We previously reported that a neurokinin 1,2-receptor antagonist FK-224 could significantly inhibit cough responses induced by capsaicin in antigen-sensitized and repeatedly challenged guinea pigs. It demonstrated that the side of action for FK-224 is in the airway and that observed cough responses are mediated by tachykinins released as a result of capsaicin exposure (44). In this study, we examined the relationship between FK-224 and TxA2 in cough responses. We observed that FK-224 significantly inhibited cough responses potentiated by STA-2 (Fig. 3). These observations confirm that tachykinins are essential in the development of a cough response to capsaicin inhalation. It seems likely that TxA2 might upregulate the sensitivity by which tachykinins could stimulate RARs and, therefore, facilitate cough responses. We found no mention of TxA2 increasing the sensitivity of tachykinins to nerve receptors. Further study is necessary to determine this hypothesis.
In this study, we investigated the actual condition of TxA2 in the airway of three groups. Concentration of TxB2 was greater in the repeatedly challenged group than in the normal and sensitized groups (Fig. 4). Our data are in agreement with results obtained in studies of asthmatic subjects by others (26, 31, 33, 40) who have shown that allergen exposure or exercise caused an increment in levels of TxA2 metabolites in plasma and urine and bronchoalveolar lavage fluid. In addition, our Northern blot analysis revealed a high expression of TxS mRNA in tracheal epithelial cells in repeatedly challenged animals compared with that in normal and sensitized animals (Fig. 9). Moreover, immunohistochemical study showed prominent staining in an increased number of mucous cells, such as goblet and bronchial gland cells of the epithelium, in repeatedly challenged animals (Fig. 6). Our in vivo data, which indicate that exogenous TxA2 potentiated cough responses in normal and immunosensitized guinea pigs but not in repeatedly challenged ones (Fig. 1), also demonstrates the increase of endogenous TxA2 in airway inflammation.
It has recently been reported that a TxS inhibitor suppressed coughing
induced by angiotensin-converting enzyme inhibitors and that the cough
threshold was increased by the treatment of OKY-046 in asthmatics
(14, 38). In the present study, OKY-046 effectively
decreased the number of coughs induced by capsaicin only in repeatedly
challenged guinea pigs (Fig. 2). However, pretreatment with AA-2414
brought a suppressed effect on the number of coughs not only in
repeatedly challenged animals but also in sensitized ones. OKY-046 is a
compound that has a highly selective effect on the inhibition of TxS.
In contrast, TxA2 is thought to bind a thromboxane-PG (TP)
receptor (10) of which the ligands are not only
TxA2 but also PGD2, PGF2
,
PGE2, and PGI2 receptors (7, 9,
10). Therefore, AA-2414 could act as an inhibitor of
prostanoids other than TxA2. These prostanoids are mediated by TP receptors in the human airway (8, 25).
PGD2 and PGF2
have also been used as tussive
agents (15). Those prostanoids could elicit coughing by
stimulation of bronchial C fibers (11, 12), probably via a
TP receptor.
The production site of TxA2 has been extensively examined in this study. It has been reported that TxA2 is produced from such cells as platelets, monocytes, macrophages, neutrophils, lung fibroblasts, and tracheal epithelial cells (16-18, 28, 43). However, the precise source of TxA2 in pathological conditions such as asthma has not yet been elucidated. Our data indicate that the production site of TxA2 in the airway was in the epithelial mucous cells (Fig. 7) and that repeated immunochallenges increased the number of those cells in the epithelium, thereby augmenting production of TxA2. Coughing is one of the major symptoms in patients with asthma and cough-variant asthma. Pathogenesis of asthma has recently been recognized to be a chronic airway inflammation. One of the causative factors of airflow limitation in asthma has been suggested to be airway hypersecretion produced by goblet cells and submucous glands (34). As a result of inflammation, goblet cells react to repeated exposure to antigens by increasing in number and bringing about hypersecretion into the airway, contributing to airflow limitation (1, 32, 34). Moreover, our data indicate that the augmented mucous cells were accompanied by the induction of TxS and elevation in airway thromboxane levels, which might explain why asthmatic subjects often experience chronic coughing. Nonadrenergic noncholinergic (NANC) nerves are distributed throughout the epithelium, innervating goblet cells and bronchial glands, and substance P, as a major neurotransmitter of NANC nerves, is one of the potent factors in mucous secretion (24). Further study is needed to clarify the relationships between mucous granules, TxA2, and NANC nerves.
In conclusion,we investigated antigen inflammation enhancing TxS expression in the airway and how this is linked to increased capsaicin-induced cough responses. In addition, we demonstrated that mucous cells within the airway are potentially an important source of TxA2 in this model of allergen-induced cough.
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Iku Sudo for preparations of tracheal tissue and Noriko Sugae for electron microphotography.
| |
FOOTNOTES |
|---|
This work was supported in part by grants from Takeda Pharmaceutical and Kissei Pharmaceutical (Japan).
Address for reprint requests and other correspondence: Y. Uchida, Dept. of Pulmonary Medicine, Institute of Clinical Medicine, Univ. of Tsukuba, Tennoudai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan (E-mail: yuchida{at}md.tsukuba.ac.jp).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 26 June 2000; accepted in final form 13 August 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aikawa, T,
Shimura S,
Sasaki H,
Ebina M,
and
Takishima T.
Marked goblet cells hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack.
Chest
101:
916-921,
1992
2.
Andersson, P.
Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs. The effect of booster injection and cyclophosphamide treatment.
Int Arch Allergy Appl Immunol
64:
249-258,
1981[Web of Science][Medline].
3.
Bartlett, DJ,
Jeffery P,
Sant'Ambrogio G,
and
Wise JCM
Location of stretch receptors in the trachea and bronchi of the dog.
J Physiol (Lond)
258:
409-420,
1976
4.
Boushey, HA,
Richardson JG,
and
Widdicombe JG.
Reflex effects of laryngeal irritation of the pattern of breathing and total lung resistance.
J Physiol (Lond)
224:
501-513,
1972
5.
Boushey, HA,
Richardson JG,
Widdicombe JG,
and
Wise JC.
The response of laryngeal afferent fibres to mechanical and chemical stimuli.
J Physiol (Lond)
240:
501-503,
1974.
6.
Coffman, TM,
Ruiz P,
Sanfilippo F,
and
Klotman PE.
Chronic thromboxane inhibition preserves function of rejecting rat renal allografts.
Kidney Int
35:
24-30,
1989[Web of Science][Medline].
7.
Coleman RA and Humphrey PPA. Prostanoid receptors: their
function and classification. In Therapeutic Applications of
Prostaglandins, edited by Vane JR and O'Grady J. London: 1993, p.
15-36.
8.
Coleman, RA,
Humphrey PPA,
Kennedy I,
and
Lumley P.
Prostanoid receptors: the development of a working classification.
Trends Pharmacol Sci
5:
303-306,
1984.
9.
Coleman RA, Kennedy I, Humphrey PPA, Bunce K, and Lumley P. Neurotransmitter and autocoid receptors. In Comprehensive
Medicinal Chemistry: The Rational Design, Mechanistic Study and
Therapeutic Application of Chemical Compounds, edited by Hansch C,
Sammes PG, and Taylor JB. Oxford, UK: 1990, p. 650-682.
10.
Coleman, RA,
and
Sheldrick RLG
Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors.
Br J Pharmacol
96:
688-692,
1989[Web of Science][Medline].
11.
Coleridge, HM,
and
Coleridge JCG
Impulse activity in afferent vagal C-fibers with endings in the intrapulmonary airway of dogs.
Respir Physiol
29:
125-142,
1977[Web of Science][Medline].
12.
Coleridge, HM,
Coleridge JCG,
Ginzel KH,
Baker DG,
Banzett RB,
and
Morrison MA.
Stimulation of irritant receptors and afferent C-fibers in the lungs by prostaglandins.
Nature
264:
451-453,
1976[Medline].
13.
Corrao, WM,
Braman SS,
and
Irwin RS.
Chronic cough as the sole presenting manifestation of bronchial asthma.
N Engl J Med
300:
633-637,
1979[Abstract].
14.
Fujimura, M,
Kamio Y,
Kasahara K,
Bando T,
Hashimoto T,
and
Matsuda T.
Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.
Eur Respir J
8:
1499-1505,
1995[Abstract].
15.
Fuller, RW,
Dixon CMS,
Dollery CT,
and
Barnes PJ.
Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine.
Am Rev Respir Dis
133:
252-254,
1986[Web of Science][Medline].
16.
Hamberg, M,
Svensson J,
and
Samuelsson B.
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Proc Natl Acad Sci USA
72:
2994-2998,
1975
17.
Higgs, GA,
Moncada S,
Salmon JA,
and
Seager K.
The source of thromboxane and prostaglandins in experimental inflammation.
Br J Pharmacol
79:
863-868,
1983[Web of Science][Medline].
18.
Hopkins, NK,
Sun FF,
and
Gorman RR.
Thromboxane A2 biosynthesis in human fibroblasts, WI-38.
Biochem Biophys Res Commun
85:
827-836,
1978[Web of Science][Medline].
19.
Iijima, H,
Uchida Y,
Endo T,
Xiang A,
Shirato M,
Nomura A,
and
Hasegawa S.
Role of endogenous nitric oxide in allergen-induced airway responses in guinea-pigs.
Br J Pharmacol
124:
1019-1028,
1998[Web of Science][Medline].
20.
Irwin, RS,
Curley FJ,
and
French CL.
Chronic cough: the spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy.
Am Rev Respir Dis
141:
640-647,
1990[Web of Science][Medline].
21.
Jammes, Y,
Fornaris E,
Mei SS,
and
Barrat E.
Afferent and efferent components of the bronchial vagal branches in cats.
J Auton Nerv Syst
5:
165-176,
1982[Web of Science][Medline].
22.
Karla, W,
Shams H,
Orr JA,
and
Scheid P.
Effect of the thromboxane A2 mimetic, U46,619, on pulmonary vagal afferents in the cat.
Respir Physiol
87:
383-396,
1992[Web of Science][Medline].
23.
Karlsson, JA,
Sant'Ambrogio G,
and
Widdicombe J.
Afferent neural pathways in cough and reflex bronchoconstriction.
J Appl Physiol
65:
1007-1023,
1988
24.
Kuo, HP,
Rohde JAL,
Tokuyama K,
Barnes PJ,
and
Rogers DF.
Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in guinea-pig trachea.
J Physiol (Lond)
431:
629-641,
1990
25.
McKenniff, M,
Rodger IW,
Norman P,
and
Gardiner PJ.
Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways.
Eur J Pharmacol
153:
149-159,
1988[Web of Science][Medline].
26.
Morris, HG,
Sherman NA,
Shepperdson FT,
and
Selner TC.
Radioimmunoassay of thromboxane B2 in plasma of normal and asthmatic subjects.
Adv Prostaglandin Thromboxane Res
8:
1759-1764,
1980[Medline].
27.
National Asthma Education and Prevention Program.
Expert Panel Report II: Guidlines for the Diagnosis and Management of Asthma., 1997.
28.
Nusing, R,
Lesch R,
and
Ulrich V.
Immunohistochemical localization of thromboxane synthetase in human tissues.
Eicosanoids
3:
53-58,
1990[Web of Science][Medline].
29.
O'Connell, EJ,
Rojas AR,
and
Sachs MI.
Cough-type asthma: a review.
Ann Allergy Asthma Immunol
66:
278-285,
1991.
30.
Ohashi, K,
Ruan KH,
Kulmacz RJ,
Wu KK,
and
Wang LH.
Primary structure of human thromboxane synthase determined from the cDNA sequence.
J Biol Chem
267:
789-793,
1992
31.
Shephard, EG,
Malan L,
MacFarlane CM,
Mounton W,
and
Joubert JR.
Lung function and plasma.
Br J Clin Pharmacol
19:
459-470,
1985[Web of Science][Medline].
32.
Shimura, S,
Andoh Y,
Haraguchi M,
and
Shirato K.
Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma.
Eur Respir J
9:
1395-1401,
1996[Abstract].
33.
Sladek, K,
Dworski R,
FitzGerald GA,
Buitkus KL,
Block FJ,
Marney SR,
and
Sheller JR.
Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin.
Am Rev Respir Dis
141:
1441-1445,
1990[Web of Science][Medline].
34.
Tamaoki, J.
Airway hypersecretion and mucociliary dysfunction in asthma.
Folia Pharmacol Jpn
111:
257-263,
1998.
35.
Tamaoki, J,
Kondo M,
Nakata J,
Nagano Y,
Isono K,
and
Nagai A.
Effect of a thromboxane A2 antagonist on sputum production and its physiochemical properties in patients with mild to moderate asthma.
Chest
118:
73-79,
2000
36.
Tone, Y,
Miyata A, S,
Hara Yukawa S,
and
Tanabe T.
Abundant expression of thromboxane synthase in rat macrophages.
FEBS Lett
340:
241-244,
1994[Web of Science][Medline].
37.
Uchida, Y,
Jun T,
Ninomiya H,
Ohse H,
Hasegawa S,
Nomura A,
Sakamoto T,
Sardessai MS,
and
Hirata F.
Involvement of endothelins in immediate and late asthmatic responses of guinea pigs.
J Pharmacol Exp Ther
277:
1622-1629,
1996
38.
Umemura, K,
Nakashima M,
and
Saruta T.
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
Life Sci
60:
1583-1588,
1997[Web of Science][Medline].
39.
Unoki, M,
Furuta S,
Onouchi Y,
Watanabe O,
Doi S,
Fujiwara H,
Miyatake A,
Fujita K,
Tamari M,
and
Nakamura Y.
Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene.
Hum Genet
106:
440-446,
2000[Web of Science][Medline].
40.
Wenzel, SE,
Westcott JY,
Smith HR,
and
Larsen GL.
Spectrum of prostanoid release after bronchoalveolar Allergen challenge in atopic asthmatics and in control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators.
Am Rev Respir Dis
139:
450-457,
1989[Web of Science][Medline].
41.
Widdicombe, JG.
Neurophysiology of the cough reflex.
Eur Respir J
8:
1193-1202,
1995[Abstract].
42.
Widdicombe, JG.
Afferent receptors in the airway and cough.
Respir Physiol
114:
5-15,
1998[Web of Science][Medline].
43.
Widdicombe, JH,
Ueki IF,
Emery D,
Margolskee D,
Yergey J,
and
Nadel JA.
Release of cycloxygenase products from primary cultures of tracheal epithelia of dog and human.
Am J Physiol Lung Cell Mol Physiol
257:
L361-L365,
1989
44.
Xiang, A,
Uchida Y,
Nomura A,
Iijima H,
Dong F,
Zhang M,
and
Hasegawa S.
Effects of airway inflammation on cough response in the guinea pig.
J Appl Physiol
85:
1847-1854,
1998
45.
Zhang, L,
Chase MB,
and
Shen RF.
Molecular cloning and expression of murine thromboxane synthase.
Biochem Biophys Res Commun
194:
741-748,
1993[Web of Science][Medline].
This article has been cited by other articles:
![]() |
Y.-L. Chou, M. D. Scarupa, N. Mori, and B. J. Canning Differential effects of airway afferent nerve subtypes on cough and respiration in anesthetized guinea pigs Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1572 - R1584. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |